MeiraGTx Holdings PLC - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
MGTX Nasdaq 2836 https://meiragtx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for MeiraGTx Holdings PLC

A Look At The Intrinsic Value Of MeiraGTx Holdings plc (NASDAQ:MGTX) - Mar 16th, 2023 10:06 am
MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results - Mar 14th, 2023 12:00 pm
JNJ Bought Up Biotech Stock MeiraGTx. It Sold Procept BioRobotics. - Feb 13th, 2023 8:00 am
MeiraGTx's Investigational Candidate Shows Improvement In Radiation Induced Dry Mouth Symptoms - Dec 13th, 2022 6:56 pm
MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia - Dec 13th, 2022 12:30 pm
MeiraGTx Holdings (NASDAQ:MGTX) investors are sitting on a loss of 71% if they invested three years ago - Dec 13th, 2022 11:26 am
MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022 - Dec 8th, 2022 9:30 pm
MeiraGTx to Participate in Upcoming Investor Conferences - Nov 22nd, 2022 9:30 pm
MeiraGTx Holdings Third Quarter 2022 Earnings: Misses Expectations - Nov 16th, 2022 11:02 am
Time To Worry? Analysts Are Downgrading Their MeiraGTx Holdings plc (NASDAQ:MGTX) Outlook - Nov 11th, 2022 3:02 pm
MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Misses Revenue Estimates - Nov 10th, 2022 2:25 pm
MeiraGTx Reports Third Quarter 2022 Financial and Operational Results and Receives $25 Million Investment from Johnson & Johnson Innovation - JJDC, Inc. - Nov 10th, 2022 1:00 pm
Institutional investors own a significant stake of 35% in MeiraGTx Holdings plc (NASDAQ:MGTX) - Nov 3rd, 2022 2:48 pm
MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress - Oct 4th, 2022 12:00 pm
Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP) - Oct 1st, 2022 2:00 pm
MeiraGTx’s Industry-Leading Gene Therapy Manufacturing Facility in Shannon, Ireland Formally Introduced by Head of Irish Government - Sep 16th, 2022 6:00 am
MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Tops Revenue Estimates - Aug 11th, 2022 1:45 pm
MeiraGTx Reports Second Quarter 2022 Financial and Operational Results - Aug 11th, 2022 12:30 pm
MeiraGTx Announces Financing Agreement with Perceptive Advisors for Up to $100 Million Secured by Manufacturing Facilities - Aug 3rd, 2022 12:00 pm
MeiraGTx Posts Encouraging Gene Therapy Data From Eye Disorder Trial - Jun 28th, 2022 6:28 pm